14. Immunologic rheumatic disorders

Richard D. Brasington, Leslie Kahl, Prabha Ranganathan, Kevin M. Latinis, Celso Velazquez, John P. Atkinson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We provide the basics for the clinician who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases, RA, SLE, Sjögren syndrome, scleroderma, and dermatomyositis/polymyositis, will be covered. In the past decade, RA is the only disease for which treatment has substantially improved. The treatment of RA has been revolutionized by the use of methotrexate and, more recently, tumor necrosis factor inhibitors. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being "elimination of synovitis equals elimination of joint destruction." The hope is that if the major mediators of Sjögren syndrome or SLE or scleroderma can be identified and then blocked, as in the example of tumor necrosis factor inhibitors in RA, more specific treatments will become available. Thus, RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology
Volume111
Issue number2 SUPPL. 2
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Systemic Lupus Erythematosus
Tumor Necrosis Factor-alpha
Therapeutics
Dermatomyositis
Synovitis
Rheumatic Diseases
Methotrexate
Joints

Keywords

  • Antiphospholipid syndrome
  • Dermatomyositis
  • Inclusion body myositis
  • Juvenile rheumatoid arthritis
  • Polymyositis
  • Rheumatoid arthritis
  • Scleroderma
  • Sjögren syndrome
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Brasington, R. D., Kahl, L., Ranganathan, P., Latinis, K. M., Velazquez, C., & Atkinson, J. P. (2003). 14. Immunologic rheumatic disorders. Journal of Allergy and Clinical Immunology, 111(2 SUPPL. 2).

14. Immunologic rheumatic disorders. / Brasington, Richard D.; Kahl, Leslie; Ranganathan, Prabha; Latinis, Kevin M.; Velazquez, Celso; Atkinson, John P.

In: Journal of Allergy and Clinical Immunology, Vol. 111, No. 2 SUPPL. 2, 01.02.2003.

Research output: Contribution to journalArticle

Brasington, RD, Kahl, L, Ranganathan, P, Latinis, KM, Velazquez, C & Atkinson, JP 2003, '14. Immunologic rheumatic disorders', Journal of Allergy and Clinical Immunology, vol. 111, no. 2 SUPPL. 2.
Brasington RD, Kahl L, Ranganathan P, Latinis KM, Velazquez C, Atkinson JP. 14. Immunologic rheumatic disorders. Journal of Allergy and Clinical Immunology. 2003 Feb 1;111(2 SUPPL. 2).
Brasington, Richard D. ; Kahl, Leslie ; Ranganathan, Prabha ; Latinis, Kevin M. ; Velazquez, Celso ; Atkinson, John P. / 14. Immunologic rheumatic disorders. In: Journal of Allergy and Clinical Immunology. 2003 ; Vol. 111, No. 2 SUPPL. 2.
@article{5bfa7719d9d34738939a9bc2333d3035,
title = "14. Immunologic rheumatic disorders",
abstract = "We provide the basics for the clinician who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases, RA, SLE, Sj{\"o}gren syndrome, scleroderma, and dermatomyositis/polymyositis, will be covered. In the past decade, RA is the only disease for which treatment has substantially improved. The treatment of RA has been revolutionized by the use of methotrexate and, more recently, tumor necrosis factor inhibitors. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being {"}elimination of synovitis equals elimination of joint destruction.{"} The hope is that if the major mediators of Sj{\"o}gren syndrome or SLE or scleroderma can be identified and then blocked, as in the example of tumor necrosis factor inhibitors in RA, more specific treatments will become available. Thus, RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed.",
keywords = "Antiphospholipid syndrome, Dermatomyositis, Inclusion body myositis, Juvenile rheumatoid arthritis, Polymyositis, Rheumatoid arthritis, Scleroderma, Sj{\"o}gren syndrome, Systemic lupus erythematosus",
author = "Brasington, {Richard D.} and Leslie Kahl and Prabha Ranganathan and Latinis, {Kevin M.} and Celso Velazquez and Atkinson, {John P.}",
year = "2003",
month = "2",
day = "1",
language = "English (US)",
volume = "111",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2 SUPPL. 2",

}

TY - JOUR

T1 - 14. Immunologic rheumatic disorders

AU - Brasington, Richard D.

AU - Kahl, Leslie

AU - Ranganathan, Prabha

AU - Latinis, Kevin M.

AU - Velazquez, Celso

AU - Atkinson, John P.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - We provide the basics for the clinician who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases, RA, SLE, Sjögren syndrome, scleroderma, and dermatomyositis/polymyositis, will be covered. In the past decade, RA is the only disease for which treatment has substantially improved. The treatment of RA has been revolutionized by the use of methotrexate and, more recently, tumor necrosis factor inhibitors. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being "elimination of synovitis equals elimination of joint destruction." The hope is that if the major mediators of Sjögren syndrome or SLE or scleroderma can be identified and then blocked, as in the example of tumor necrosis factor inhibitors in RA, more specific treatments will become available. Thus, RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed.

AB - We provide the basics for the clinician who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases, RA, SLE, Sjögren syndrome, scleroderma, and dermatomyositis/polymyositis, will be covered. In the past decade, RA is the only disease for which treatment has substantially improved. The treatment of RA has been revolutionized by the use of methotrexate and, more recently, tumor necrosis factor inhibitors. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being "elimination of synovitis equals elimination of joint destruction." The hope is that if the major mediators of Sjögren syndrome or SLE or scleroderma can be identified and then blocked, as in the example of tumor necrosis factor inhibitors in RA, more specific treatments will become available. Thus, RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed.

KW - Antiphospholipid syndrome

KW - Dermatomyositis

KW - Inclusion body myositis

KW - Juvenile rheumatoid arthritis

KW - Polymyositis

KW - Rheumatoid arthritis

KW - Scleroderma

KW - Sjögren syndrome

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0037326533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037326533&partnerID=8YFLogxK

M3 - Article

C2 - 12592305

AN - SCOPUS:0037326533

VL - 111

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2 SUPPL. 2

ER -